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Abstract: The miRNA expression profiles of skin biopsies from 14
primary cutaneous anaplastic large cell lymphoma (C-ALCL)
patients were analysed with miRNA microarrays using the same
control group of 12 benign inflammatory dermatoses (BID) as
previously used to study the miRNA expression profile of tumor-
stage mycosis fungoides (MF). We identified 13 differentially
expressed miRNAs between C-ALCL and BID. The up-regulation of
miR-155, miR-27b, miR-30c and miR-29b in C-ALCL was validated
by miRNA-Q-PCR on independent study groups. Additionally, the
miRNA expression profiles of C-ALCL were compared with those of
tumor-stage MF. Although miRNA microarray analysis did not
identify statistically significant differentially expressed miRNAs,
miRNA-Q-PCR demonstrated statistically significantly differential
expression of miR-155, miR-27b, miR-93, miR-29b and miR-92a
between tumor-stage MF and C-ALCL. This study, the first
describing the miRNA expression profile of C-ALCL, reveals
differences with tumor-stage MF, suggesting a different
contribution to the pathogenesis of these lymphomas.
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Background
Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is char-
acterized by large cells with an anaplastic, pleomorphic or immunob-
lastic cytomorphology and by expression of the CD30 antigen by
more than 75% of the tumor cells (1). Although its histology indi-
cates an aggressive lymphoma, C-ALCL often shows an indolent clin-
ical behaviour with a 10-year disease-specific survival (DSS) of
approximately 90% (2–4). The molecular mechanisms involved in
the development of this disorder are largely unknown (5).
MicroRNAs (miRNAs) are small non-coding RNA molecules
that regulate gene expression posttranscriptionally. They may have
oncogenic or tumor suppressing properties depending on their
target genes (6,7). Several studies have demonstrated specific
miRNA expression profiles in different types of CTCL suggesting a
role in the pathogenesis of these disorders (8–12). For instance,
recently, van Kester et al. (8) have elaborated on the miRNA
expression profile of tumor-stage mycosis fungoides (MF), a
CTCL with a 10-year DSS of 42%. So far, only one study focusing
on the miRNA expression profiling of CTCL in general has
included C-ALCL biopsies (10). Hence, the miRNA expression
profile of C-ALCL is as yet unknown.
Questions addressed
The aim of this study was to determine the miRNA expression
profile of C-ALCL compared with benign inflammatory dermato-
ses (BID) and with tumor-stage MF to identify miRNAs which
may contribute to the pathogenesis of these malignancies.
Experimental design
For detailed material and methods, please see Supporting informa-
tion (Data S1). Formalin fixed paraffin embedded (FFPE) skin
biopsies containing more than 75% of CD30+ large cells were
selected from 21 C-ALCL patients. In total, 14 biopsies
were selected for array analysis, and seven additional biopsies were
selected as a test group for validation by miRNA-Q-PCR. As a
control group, FFPE biopsies of 12 benign inflammatory
dermatoses (BID) containing T-cell-rich infiltrates were selected:
five eczema and seven lichen planus cases for array analysis and
five additional eczema and six lichen planus cases for miRNA-Q-
PCR.
The complete miRNA profile of samples was elucidated using
lRNA microarrays (8,14). The arrays were used within 3 months
after printing. ANOVA analysis was performed to identify
miRNAs differentially expressed between sample types, and multi-
ple testing correction was done using the Benjamini–Hochberg
method.
Results of miRNA microarray analysis of C-ALCL were com-
pared with those recently published on 19 tumor stage MF (8),
which were generated using the same platform (9).
MiRNA cDNA synthesis was performed as described before (8).
MiRNA-Q-PCR was performed using Taqman miRNA assays and
29 Universal PCR mastermix (Applied Biosystems-Life Technolo-
gies, Carlsbad, CA, USA). All reactions were run on the Light-
Cycler480 (Roche, Almere, the Netherlands), according to
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manufacturer’s protocol (Applied Biosystems). MiRNA expression
levels were analysed using the ΔCt method expressed relative to
U6.
Results
MiRNA microarray analysis showed twelve miRNAs higher
expressed and one miRNA lower expressed in C-ALCL compared
with BID (adjusted P < 0.05; Table S1). To validate these results,
miRNA-Q-PCR was performed for miR-155, miR-29b, miR-30c
and miR-27b in an additional group of C-ALCL (n = 7) and BID
(eczema n = 5 and lichen planus n = 6). All miRNA-Q-PCR
results are consistent with the microarray data, showing significant
differential expression between C-ALCL and BID (P < 0.05;
Fig. 1a).
Comparison of miRNA microarray results from C-ALCL with
those from tumor-stage MF showed differential expression of sev-
eral miRNAs, but none remained statistically significant after
p < 0.01 p < 0.01
p = 0.01 p = 0.02
p < 0.01 p < 0.01




Figure 1. Expression levels of selected miRNAs as measured by miRNA-Q-PCR in
an additional test group. Horizontal bars represent the mean. (a) Confirmation of
four miRNAs selected for validation. (b) Four of five miRNAs additionally tested are
significant differentially expressed between C-ALCL and benign controls (P-values
measured by Mann–Whitney U-test).
p = 0.02p < 0.01
p = 0.04 p = 0.05
p = 0.05
Figure 2. Expression levels of miR-155, miR-27b, miR-93, miR-29b and miR-92a as
measured by miRNA-Q-PCR in C-ALCL and tumor-stage MF. Horizontal bars
represent the mean (P-values measured by Mann–Whitney U-test).
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multiple testing correction. However, we noticed that the set of
miRNAs discriminating C-ALCL from benign controls (this study)
is different from the set discerning tumor-stage MF from the same
controls (8). We therefore extended the analysis of C-ALCL and
used miRNA-Q-PCR to determine the expression of miR-93,
miR-92a, miR-30b, miR-16 and miR-383, which were differentially
expressed between tumor-stage MF and BID. Except for miR-383,
all miRNAs showed significant up-regulation in C-ALCL vs. BID
(Fig. 1b). In analogy, we also measured miR-29b and miR27b in
tumor-stage MF, using the validation set as described by van Kest-
er et al. (8), resulting in the up-regulation of miR-29b in tumor-
stage MF vs. BID (P < 0.01), while miR-27b is not differentially
expressed (data not shown). Finally, we determined whether any
of the miRNAs assayed by miRNA-Q-PCR is differentially
expressed between C-ALCL and MF. As depicted in Fig. 2, this
analysis identified differential expression of miR-155, miR-27b,
miR-93, miR-92a and miR-29b.
Conclusions
Using miRNA microarrays, we found thirteen miRNAs differen-
tially expressed between C-ALCL and BID, twelve up-regulated
and one down-regulated. We validated expression of miRNA-155,
miR-27b, miR-30c and miR-29b with miRNA-Q-PCR in two
independent groups of C-ALCL and BID. Because these array-
based analyses of miRNA profiles of C-ALCL were performed
using the same platform as the recently published experiments on
miRNA profiling of tumor-stage MF, a proper comparison
(including normalization and statistical analysis) was feasible
(8,9). Under stringent statistical conditions, no differences between
C-ALCL and MF were identified. However, the miRNA-Q-PCR-
based analysis of an additional selection of individual miRNAs
(chosen as being differentially expressed between tumor-stage MF
or C-ALCL and BID) revealed not only further differences
between the two disease entities (miR-155, miR-27b, miR-93,
miR-92a and miR-29b) but also additional differences between
C-ALCL and BID (miR-93, miR-92a, miR-27b, miR-30b and miR-
16). Therefore, miRNA arrays are well suited for initial genome-
wide screening, but apparently are less sensitive for detection of
more subtle changes in miRNA expression. A similar observation
was recently made by Ralfkiaer et al. (10) in the course of their
miRNA profiling studies for diagnostic markers of CTCL who
speculated that this might relate to cross-hybridization problems
or a restricted dynamic range of miRNA microarrays. Moreover,
miRNA microarrays are only capable of measuring the relative
expression levels of known (annotated) miRNAs, and hitherto
unknown miRNAs might be differentially expressed between the
different disease entities as well. These restrictions might be over-
come in the future using techniques like next generation deep
sequencing, though the limited availability of suitable (frozen)
material with a high tumor cell content will remain a challenge.
The current miRNA expression profile of C-ALCL and the differ-
ences compared with tumor-stage MF provide a framework for
further (functional) studies and may help to reveal the molecular
pathogenesis of these lymphomas.
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